Patients with type 2 diabetes and mild renal impairment experienced improved glycemic control when treated with ipragliflozin… According to lead author Atsunori Kashiwagi, MD, PhD, of Kusatsu General Hospital in Shiga, among patients with mild renal impairment, patients receiving ipragliflozin had a mean decrease in HbA1c of 0.56% at 6 …
Read More »FDA Approves Xigduo XR, a New Dapagliflozin-Metformin Combination
The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …
Read More »The Role of Glutamine in Human Carbohydrate Metabolism in Kidney and Other Tissues
Glutamine is the most abundant amino acid in the human body and is involved in more metabolic processes than any other amino acid. Recent studies using isotopic and balance techniques have greatly advanced the understanding of glutamine metabolism in humans and its role in glucose metabolism in the kidney and other …
Read More »SGLT-2 Inhibitor May Reduce Blood Pressure for Type 2s
SGLT-2 inhibitor use in the management of glucose in type 2 diabetes could reduce blood pressure in patients with hypertension…. In a new study, researchers found that empagliflozin lowered blood pressure in patients with type 2 diabetes and hypertension. Hypertension affects about two-thirds of patients with diabetes. See more …
Read More »Potential of SGLT2 Inhibitors in Type 1 Diabetes
Pilot study shows that an SGLT-2 inhibitor doses of 5-mg and 10-mg were associated with significant reductions in blood glucose and total daily insulin dose…. Dapagliflozin is a member of the SGLT2 inhibitor class of diabetic medications indicated only for treatment of type 2 diabetes. Dapagliflozin helps reduce blood glucose …
Read More »Stanley Schwartz, MD: Positive Effects of More Aggressive Treatment
Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, …
Read More »An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
This week, we are taking a break from our Clinical Text presentations, to bring you this exclusive interview with Al Mann, the legendary founder of Mannkind Corp, and the person primarily responsible for backing the development of the inhaled insulin product, Afrezza, soon to be on the market. Steve Freed: …
Read More »SGLT2 Inhibitors as Add-On for Poorly Controlled Patients on DPP-4s and Metformin
As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s …
Read More »Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
The glucose-reducing drug empagliflozin (Jardiance) now has approval from the FDA after the drug maker corrected manufacturing problems that caused the agency to say “no” in March…. The sodium glucose cotransporter 2 (SGLT2) is indicated for improving glycemic control in adults with type 2 diabetes in conjunction with diet and …
Read More »Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 4
In this last of a comprehensive series of four Homerun Slides sets on SGLT-2 inhibitors, we delve deeper into how this drug class can work in challenging patient populations, incuding older and renally-impaired patients. In addition, the beneficial effects on weight and blood pressure are discussed…. To download the complete …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.